New-generation Antipsychotic Drugs May Have Similar Neurological Side-effects To Conventional Drugs (p 1581)May 07, 2003Authors of a systematic review of antipsychotic drugs in this week's issue of THE LANCET highlight how the better side-effect profile of new-generation drugs may not be as substantial as previously thought when compared with conventional antipsychotics. New-generation drugs are generally more efficacious, although older-generation antipsychotics are still a cost-effective option for treating disorders such as schizophrenia in resource-poor settings. The main advantage of new-generation antipsychotic drugs is a reduced risk of side-effects compared with conventional drugs. However, there is debate that the reduced side-effects of the new-generation class of drugs is based on trials that could have been biased due to comparisons with the high-potency antipsychotic drug haloperidol. Stefan Leucht from the Zucker Hillside Hospital, New York, USA, and colleagues reanalysed all previous randomised controlled trials where new-generation antipsychotics had been compared with low-potency conventional drugs. 31 studies which involved 2320 patients were identified. Of the new generation drugs, only clozapine was associated with fewer neurological side-effects and higher efficacy than low-potency conventional drugs. As a group, new-generation drugs were moderately more efficacious than low-potency antipsychotics. Stefan Leucht comments: "Optimum doses of low-potency conventional antipsychotics might not induce more neurological side-effects than new generation drugs. Potential advantages in efficacy of the new-generation drugs should be a factor in clinical treatment decisions to use these rather than conventional drugs. However, if these findings are confirmed by future studies, there would be a good argument for the use of appropriately dosed conventional drugs-such as chlorpromazine-for patients with schizophrenia in settings where new-generation drugs are not generally affordable." | |||||||||||||||||||||
|
Related Schizophrenia News Articles Severe, acute maternal stress linked to the development of schizophrenia Pregnant women who endure the psychological stress of being in a war zone are more likely to give birth to a child who develops schizophrenia. Unlocking mystery of why dopamine freezes Parkinson's patients Parkinson's disease and drug addiction are polar opposite diseases, but both depend upon dopamine in the brain. Parkinson's patients don't have enough of it; drug addicts get too much of it. Although the importance of dopamine in these disorders has been well known, the way it works has been a mystery. Human brains pay a price for being big Metabolic changes responsible for the evolution of our unique cognitive abilities indicate that the brain may have been pushed to the limit of its capabilities. Research published today in BioMed Central's open access journal Genome Biology adds weight to the theory that schizophrenia is a costly by-product of human brain evolution. Estrogen relieves psychotic symptoms in women with schizophrenia When combined with antipsychotic medications, the estrogen estradiol appears to be a useful treatment in women with schizophrenia, according to a report in the August issue of Archives of General Psychiatry, one of the JAMA/Archives journals. N.Y. Research Team Discovers How Antidepressants and Cocaine Interact with Brain Cell Targets In a first, scientists from Weill Cornell Medical College and Columbia University Medical Center have described the specifics of how brain cells process antidepressant drugs, cocaine and amphetamines. These novel findings could prove useful in the development of more targeted medication therapies for a host of psychiatric diseases, most notably in the area of addiction. Study Shows Promising Results in Deep Brain Stimulation for Treatment-Resistant Depression New data from a study of patients with treatment-resistant depression who underwent deep brain stimulation (DBS) in the subcallosal cingulate region (SCG or Cg25) of the brain shows that this intervention is generally safe and provides significant improvement in patients as early as one month after treatment. The patients also experienced continued and sustained improvement over time. Protein marker for schizophrenia risk A protein found in immune cells may be a reliable marker for schizophrenia risk, report researchers in a new proteomics study appearing in the July issue of Molecular and Cellular proteomics. Schizophrenia linked to dysfunction in molecular brain pathway activated by marijuana Alterations in a molecular brain pathway activated by marijuana may contribute to the cognitive symptoms of schizophrenia, according to a report in the July issue of Archives of General Psychiatry, one of the JAMA/Archives journals. Violence declines with medication use in some with schizophrenia Some schizophrenia patients become less prone to violence when taking medication, but those with a history of childhood conduct problems continue to pose a higher risk even with treatment, according to a new study by researchers at Duke University Medical Center. NARSAD Researchers Identify Specific Genes and Family Traits Linked to Schizophrenia, Bipolar Disorder and Depression New findings from research supported by NARSAD, the world's leading charity dedicated to mental health research, and conducted by Harvard-affiliated scientists are providing important clues into how genes work to impair various aspects of attention, memory and perception -- the behaviors associated with many psychiatric illnesses, such as schizophrenia, bipolar disorder and depression. More Schizophrenia News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||